Today the United States Supreme Court ruled on the validity of BRAC1 and BRAC2 human gene patents stating that, ‘A naturally occurring DNA segment is a product of nature and not patent eligible merely because it has been isolated, but cDNA is patent eligible because it is not naturally occurring,’ is consistent with our views on gene patents and is one we support. This ruling is good news for the biotech industry as it clarifies the rules and reduces uncertainty.
Rockville, MD – June 29, 2005 – Synthetic Genomics, Inc., a new company that will develop and commercialize synthetic biology, was launched today. The Company will engineer modular “cassette” based systems to execute specific functions using reprogrammed cells as bio-factories. Synthetic Genomics, Inc.’s initial focus will be on ethanol and hydrogen production. After leveraging enormous archives of genomic sequence data, the Company will integrate novel processes to design, build, and test desired outputs from synthetic organisms.